Results 51 to 60 of about 302,791 (267)

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

Molecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk   +4 more
wiley   +1 more source

CHIP Chaperones Wild Type p53 Tumor Suppressor Protein [PDF]

Journal of Biological Chemistry, 2007
Wild type p53 exists in a constant state of equilibrium between wild type and mutant conformation and undergoes conformational changes at elevated temperature. We have demonstrated that the co-chaperone CHIP (carboxyl terminus of Hsp70-interacting protein), which suppressed aggregation of several misfolded substrates and induced the proteasomal ...
Veenu, Tripathi, Amjad, Ali, Rajiv, Bhat, Uttam, Pati   +3 more
openaire   +2 more sources

Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells

Molecular Oncology, EarlyView.
We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller, Susanne Ebner, Carmen Haselrieder, Julia K. Günther, Astrid Drasche, Sophie Strich, Chiara Volani, Andrea Medici, Aleksandar Nikolajevic, Alex Deltedesco, Johannes E. Sigmund, Michael J. Blumer, Martin Hermann, Johanna Vanacker, Gerald Brandacher, Eduard Stefan, Omar Torres‐Quesada, Jakob Troppmair   +17 more
wiley   +1 more source

Interaction of metallothionein with tumor suppressor p53 protein [PDF]

FEBS Letters, 2006
Previous reports have shown that metallothionein (MT) may modulate p53 activity through zinc exchange. However, little is known on a direct interaction between MT and p53 in cells. The results demonstrate an interaction between MT and p53 can occur in vitro.
Ostrakhovitch, Elena A., Olsson, Per-Erik, Jiang, Sean, Cherian, M. George   +3 more
openaire   +2 more sources

Identification of novel pQTL‐SNPs associated with lung adenocarcinoma risk: A multi‐stage study

Cancer Medicine
Background and Objective To explore the association between protein quantitative trait loci (pQTL‐SNPs) and the risk of LUAD. Methods “Blood +” high depth blood proteomics analysis was performed on plasma from female LUAD patients and female healthy ...
Yutong Wu, Huiwen Xu, Liping Mao, Rongrong Zhao, Junfeng Chu, Lili Huang, Wendi Zhang, Yiran Liu, Qiong Chen, Xiaobo Tao, Siqi Li, Shenxuan Zhou, Anhui Ning, Zhenyu Li, Tian Tian, Lei Zhang, Jiahua Cui, Guangyu Tian, Minjie Chu   +18 more
doaj   +1 more source

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

Molecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken, Andrea Abel Gutierrez, Imke van Rossum, Cornelia G. Spruijt, Michiel Vermeulen, Guido van Mierlo, Blanca Scheijen, Annemiek B. van Spriel   +7 more
wiley   +1 more source

The tumor suppressor protein p150Sal2 in carcinogenesis

Tumor Biology, 2015
The transcription factor p150(Sal2), the product of the SALL2 gene, was first identified as a binding target of the oncogenic mouse polyomavirus T antigen. However, mouse polyomavirus is not the only oncogenic virus that targets p150(Sal2); the human papillomavirus E6 protein also targets this cellular protein in order to overcome p150(Sal2)-mediated ...
Chang Kyoo, Sung, Hyungshin, Yim
openaire   +2 more sources

Hsp90 Chaperones Wild-type p53 Tumor Suppressor Protein [PDF]

Journal of Biological Chemistry, 2004
Immortalized human fibroblasts were used to investigate the putative interactions of the Hsp90 molecular chaperone with the wild-type p53 tumor suppressor protein. We show that geldanamycin or radicicol, specific inhibitors of Hsp90, diminish specific wild-type p53 binding to the p21 promoter sequence.
Dawid, Walerych, Grzegorz, Kudla, Malgorzata, Gutkowska, Bartosz, Wawrzynow, Lin, Muller, Frank W, King, Aleksandra, Helwak, Joanna, Boros, Alicja, Zylicz, Maciej, Zylicz   +9 more
openaire   +2 more sources

The novel fusion proteins, GnRH-p53 and GnRHIII-p53, expression and their anti-tumor effect. [PDF]

PLoS ONE, 2013
p53, one of the most well studied tumor suppressor factor, is responsible to a variety of damage owing to the induction of apoptosis and cell cycle arrest in the tumor cells.
Peiyuan Jia, Yu Zhao, Shaoping Wu, Junhua Wu, Shan Gao, Ying Tong, Yuxia Wang   +6 more
doaj   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source